OneSource Specialty Pharma Ltd
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]
- Market Cap ₹ 14,583 Cr.
- Current Price ₹ 1,274
- High / Low ₹ 1,800 / 1,255
- Stock P/E
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE -11.8 %
- ROE -45.5 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -47.7% over last 3 years.
- Debtor days have increased from 84.7 to 118 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Miscellaneous Industry: Miscellaneous
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 21 | 132 | 39 | 172 | |
| 93 | 228 | 156 | 254 | |
| Operating Profit | -72 | -96 | -117 | -82 |
| OPM % | -337% | -72% | -303% | -48% |
| 1 | 4 | -525 | -143 | |
| Interest | 16 | 68 | 48 | 89 |
| Depreciation | 34 | 70 | 109 | 76 |
| Profit before tax | -121 | -230 | -799 | -390 |
| Tax % | 0% | 0% | 0% | 0% |
| -121 | -230 | -799 | -390 | |
| EPS in Rs | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 100% |
| TTM: | 344% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 58% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -48% |
| Last Year: | -45% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|
| Equity Capital | 2 | 4 | 4 | 4 | 4 |
| Reserves | 777 | 1,012 | 783 | 394 | 403 |
| 386 | 1,154 | 864 | 571 | 612 | |
| 98 | 275 | 363 | 457 | 264 | |
| Total Liabilities | 1,262 | 2,445 | 2,014 | 1,426 | 1,283 |
| 633 | 1,231 | 1,361 | 863 | 972 | |
| CWIP | 382 | 440 | 334 | 188 | 43 |
| Investments | 53 | 52 | 5 | 20 | 11 |
| 194 | 722 | 314 | 355 | 257 | |
| Total Assets | 1,262 | 2,445 | 2,014 | 1,426 | 1,283 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| -115 | -420 | -165 | -109 | |
| -210 | -685 | -66 | 506 | |
| 381 | 1,159 | 118 | -384 | |
| Net Cash Flow | 56 | 55 | -112 | 13 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 38 | 101 | 35 | 118 |
| Inventory Days | 87 | 1,720 | 2,354 | 665 |
| Days Payable | 758 | 408 | 1,606 | 419 |
| Cash Conversion Cycle | -633 | 1,414 | 784 | 363 |
| Working Capital Days | -1,116 | 251 | -1,939 | -255 |
| ROCE % | -10% | -12% | -12% |
Documents
Announcements
- Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 1d
-
Announcement under Regulation 30 (LODR)-Credit Rating
1d - Credit rating upgraded; merger and equity infusion completed.
-
Announcement under Regulation 30 (LODR)-Change in Management
1d - Termination of Chief Business Officer, Jason T Spacek.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2d - Of schedule of Institutional Investors meet (physical meet) scheduled on Tuesday, February 25, 2025 at 9:00 am IST.
-
Announcement under Regulation 30 (LODR)-Change in Management
14 Feb - Appointment of Bernhard Thurnbauer as Chief Quality Officer.
Annual reports
No data available.
Concalls
-
Feb 2025Transcript PPT
Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.